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Case Report
Introduction
Chronic lymphocytic leukemia (CLL) is a progressive, lym-
phocytic disorder characterized by accumulation of imma-
ture, functionally incompetent lymphocytes. Staging is 
typically done via the Rai and Binet systems, both of which 
are based on the presence and degree of disease-related ane-
mia, thrombocytopenia, and organomegaly (Tables 1 and 2). 
Treatment with chemoimmunotherapy or small molecular 
inhibitors is typically indicated for high-risk disease (eg, 
Binet stage C or Rai stage III/IV) and select cases of interme-
diate disease (Binet stage B or Rai stage I/II).1 Renal involve-
ment such as nephrotic syndrome is rare and poorly 
described.2 We present a case of a 56-year-old male with 
CLL who presented with nephrotic range proteinuria and 
venous thromboemboli, both of which subsequently resolved 
with treatment of his CLL.
Case Report
A 57-year-old male with no prior medical history presented to 
an outside hospital with progressive fatigue, decreased exercise 
tolerance, and lower extremity edema of 3 months duration. 
No lymphadenopathy or hepatosplenomegaly was noted on 
exam. Laboratory tests were significant for a leukocytosis of 
95 200/µL with 84% lymphocytes, smudge cells on periph-
eral smear, hemoglobin 13.2 g/dL, platelet count 177 000/µL, 
creatinine 1.2 mg/dL, serum albumin 2.1 g/dL, and hemoglo-
bin A1c of 5.7% (Table 3). No prior laboratory tests were 
available for comparison, as the patient had not seen a physi-
cian in several years. Peripheral blood immunophenotyping 
showed a monoclonal population of cells positive for CD5, 
CD19, CD20, CD22, and CD23 and negative for CD38, an 
immunophenotype that is consistent with CLL. Peripheral 
blood fluorescent in situ hybridization was positive for tri-
somy 12 and negative for del(11p), del(13q), and del(17q). 
ZAP70 and immunoglobulin heavy-chain variable-region 
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Abstract
Chronic lymphocytic leukemia (CLL) is a chronic, progressive lymphoproliferative disorder characterized by a monoclonal 
population of functionally incompetent lymphocytes. Renal involvement is rare and poorly described. A 57-year-old male 
with no prior medical history was diagnosed with CLL and followed with a watch and wait approach. He was referred to 
our institution several months later due to concern for Richter’s transformation to diffuse large B-cell lymphoma. A positron 
emission tomography/computed tomography scan showed no evidence of diffuse large B-cell lymphoma; however, the patient 
was noted to have hypoalbuminemia, nephrotic range proteinuria, an acute left renal vein thrombus, and a right pulmonary 
embolus. A nephrotic syndrome workup including autoimmunity and infection was unremarkable, and a kidney biopsy was 
deferred due to concern for renal compromise in the setting of a renal vein thrombus. The patient was treated with 6 cycles 
of reduced-dose fludarabine, cyclophosphamide, and rituximab for a presumed CLL-associated nephrotic syndrome and 
anticoagulation for his venous thromboemboli. At 6-month follow-up, the patient achieved complete remission of his CLL 
with normalization of all cell lines and resolution of his nephrotic range proteinuria. Repeat computed tomography scans 
showed no evidence of recurrent venous thromboemboli. This case demonstrates a potential role of empiric chemotherapy 
in cases of CLL-associated nephrotic syndrome given its potentially life-threatening sequelae and response to treatment.
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mutations were also negative. Serum β-2 microglobulin was 
elevated at 3.7 µg/mL (normal 0-3 µg/mL). The patient was 
diagnosed with Rai stage 0 CLL and was followed with a 
watch and wait approach until approximately 6 months after-
ward when a computed tomography (CT) scan reportedly 
showed a left lower quadrant mass concerning for possible 
Richter’s transformation to diffuse large B-cell lymphoma. 
He was subsequently referred to our institution for further 
evaluation.
On admission, physical exam was significant for bilateral 
axillary and inguinal lymphadenopathy, hepatomegaly, 
splenomegaly, and diffuse anasarca with pronounced scrotal 
edema. Laboratory tests were notable for a leukocytosis 77 
000/µL with 93% lymphocytes, hemoglobin 11.5 g/dL, 
platelet count 174 000/µL, creatinine 1.3 mg/dL, estimated 
creatinine clearance (CrCl) of 95 mL/min, and serum albu-
min 1.4 g/dL (Table 3). Platelets, serum electrolytes, trans-
aminases, alkaline phosphatase, total bilirubin, and 
international normalized ratio were within normal limits. 
Repeat peripheral blood flow cytometry confirmed CLL with 
a monoclonal population of cells with the immunophenotype 
previously noted along with negative expression of CD34, 
CD117, and FMC7. Urinalysis showed 3+ protein, and a 
24-hour urine protein collection showed 11 g/24 h (normal 
<150 mg/24 h). The high-grade proteinuria, hypoalbumin-
emia, and anasarca confirmed the diagnosis of nephrotic syn-
drome. The patient also underwent a whole-body positron 
emission tomography/CT scan to evaluate for possible 
Richter’s transformation. Diffuse mesenteric, inguinal, and 
retroperitoneal lymphadenopathy was noted consistent with 
Rai Stage II, but there was no evidence of hypermetabolic 
masses concerning for diffuse large B-cell lymphoma. 
However, an acute right pulmonary embolus (Figure 1) and a 
left renal vein thrombus (Figure 2) were noted on CT. The 
patient was started on low-molecular-weight heparin while 
undergoing further evaluation for his nephrotic-range 
proteinuria.
Antinuclear antibody, HIV, hepatitis B/C, and phospholi-
pase-A2 receptor antibody titers were negative. Serum and 
urine protein electrophoresis showed decreased and increased 
total protein, respectively, but were otherwise unremarkable. 
Serum κ and λ light chains were within normal limits, and no 
urine Bence-Jones proteins, dysmorphic cells, or casts were 
detected. A kidney biopsy was deferred due to concern for 
risk of bleeding in the setting of renal vein thrombosis and 
anticoagulation. Therefore, it was concluded that the patient’s 
nephrotic syndrome and venous thromboemboli, a known 
complication of nephrotic syndrome, were due to CLL given 
his otherwise unremarkable nephrotic syndrome workup. He 
was started on 6 cycles of reduced-dose fludarabine, cyclo-
phosphamide, and rituximab (FCR-Lite) chemotherapy and 
continued on low-molecular-weight heparin.3 At 6-month 
follow-up, the patient achieved complete remission of his 
CLL with normalization of all cell lines, serum creatinine, 
hypoalbuminemia, and nephrotic range proteinuria (Table 3). 
No lymphadenopathy was noted, and repeat CT scans 
showed no evidence of recurrent venous thromboemboli.
Discussion
Kidney involvement is an uncommon but potentially serious 
sequela of CLL, can occur at any stage of CLL, and should 
be considered as a leading diagnosis once other causes of 
renal impairment have been considered. Membrano-
proliferative glomerulonephritis (MPGN) is the most com-
mon cause of CLL-associated renal involvement, with 
CLL-cell infiltration, thrombotic microangiopathy (TMA), 
and minimal change disease as other notable etiologies.4 
Cases of CLL-associated focal segmental glomerulosclerosis 
have been reported as well.5
Evaluation involves a thorough history and physical 
exam, urinalyses, and serologies to evaluate for other causes 
of nephrotic and/or nephritic syndromes, for example, auto-
immunity, infection, and so on. Anti-phospholipase A2 
receptor antibodies are often used in evaluation of idiopathic 
membranous nephropathy; however, their role in CLL-
associated renal impairment is less well established.6,7 
Diagnosis often ultimately entails a renal biopsy in order to 
differentiate among the different etiologies of kidney damage.1,5 
This is especially important given the differences in manage-
ment and prognosis. For instance, several cases of renal 
TMA diagnosed on biopsy resolved after discontinuation of 
chemotherapy, in particular pentostatin, that itself has been 
associated with TMA.4 Conversely, CLL-associated MPGN 
Table 1. Binet Clinical Staging for Chronic Lymphocytic 
Leukemia1.
Stage Description
A One to 2 enlarged lymphoid areas (eg, cervical, 
axillary, inguinofemoral, spleen, liver)
B Thee or more enlarged lymphoid areas
C Presence of anemia (hemoglobin <10.0 g/dL) or 
thrombocytopenia (platelets <100 000/µL)
Table 2. Modified Rai Clinical Staging for Chronic Lymphocytic 
Leukemia1.
Risk Stage Description
Low 0 Lymphocytosis (eg, lymphoid cells >30% 
cells in blood or marrow)
Intermediate I Lymphocytosis and lymphadenopathy
II Lymphocytosis with enlarged spleen or 
liver, with or without lymphadenopathy
High III Lymphocytosis with anemia (hemoglobin 
<11.0 g/dL), with or without enlarged 
spleen, liver, or lymph nodes
IV Lymphocytosis with thrombocytopenia 
(platelets <100 000/µL)
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appears to respond well to alkylating agents, in particular 
cyclophosphamide, especially given their existing use in 
treating idiopathic MPGN.4
It is unclear if any specific CLL stage, mutation, or sero-
logic marker predisposes to a higher or lower risk of CLL-
associated kidney injury. The Rai and Binet staging systems 
are typically used to determine prognosis and/or decision to 
initiate treatment. However, these are based on physical exam 
and complete blood count, and do not include existing or 
future risk of kidney function/impairment. Trisomy 12 and 
del(13q) have been associated with favorable prognoses (eg, 
progression-free survival, response to treatment, etc), while 
del(11q), del(17q), CD38, immunoglobulin heavy chain vari-
able region gene mutations, and elevated β-2 microglobulin 
levels have been associated with poor prognoses.5 However, a 
single-center case series of 49 patients with biopsy-proven 
CLL-associated renal injury including nephrotic syndrome 
showed no predominant mutations, immunophenotypes, or 
serologic markers.4 Another multicenter case series of 15 
similar patients was also inconclusive.8 Further work such as 
a systematic review with a larger sample size may elucidate 
further insight into potential genetic and/or serologic risk fac-
tors of CLL-associated renal injury.
Kidney involvement also has potential implications 
toward CLL treatment. Currently, there is no standard regi-
men and/or agent(s) for treatment of symptomatic CLL. 
Specific agents include purine analogs (eg, fludarabine, pen-
tostatin), alkylating agents (eg, chlorambucil, cyclophospha-
mide, bendamustine), monoclonal antibodies (eg, rituximab), 
and Bruton’s tyrosine kinase inhibitors (eg, ibrutinib). Most 
young (<70 years), previously untreated patients with intact 
Table 3. Summary of Laboratory Tests.
Parameter
Six Months Prior 
to Admission
On 
Admission
Prior to 
Chemotherapy
Six Months After 
Chemotherapy
White blood cell count  
(normal 4500-11 000/mm3)
95.2 77.0 72.0 4.3
Hemoglobin (normal 13.5-17.5 g/dL) 13.2 11.5 10.7 13.9
Platelet count  
(normal 13 000-400 000/mm3)
177 174 178 174
Creatinine (normal 0.44-1.27 mg/dL) 1.2 1.3 1.24 0.77
Albumin (normal 3.5-5.5 g/dL) 2.1 1.4 1.4 3.8
Lactate dehydrogenase  
(normal 90-200 U/L)
322 — 242 —
Figure 1. Computed tomography scan of chest with contrast. 
Large acute pulmonary embolus involving the right pulmonary 
artery extending into the interlobar artery and its branches 
(yellow arrow).
Figure 2. Computed tomography scan of abdomen/pelvis with 
contrast. Left renal vein thrombus with total luminal occlusion 
and extension into the inferior vena cava (yellow arrow), 
along with diffuse lymphadenopathy (periportal, mesenteric, 
retroperitoneal), hepatomegaly, and splenomegaly.
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renal function are treated with fludarabine-based therapy 
including cyclophosphamide and/or and rituximab (FCR and 
FR, respectively), as these regimens have demonstrated 
superior response rates and progress-free survival in this 
patient population when compared with other regimens (eg, 
chlorambucil-based).3 However, CrCl is one of the strongest 
predictors of fludarabine toxicity, as such non-fludarabine 
regimens are often chosen in patients with an estimated CrCl 
<80 mL/min.9 Bendamustine plus rituximab appears to be 
slightly less effective but with similar overall survival rates 
and less toxic effects when compared with FCR.10 
Chlorambucil is also sometimes used for cases of CLL with 
renal impairment, but this has shown to be inferior to fluda-
rabine- and bendamustine-based reigmens.3,11
In the case of our patient, his profound anasarca, hypoal-
buminemia, proteinuria, venous thromboemboli, normal 
transaminases, and international normalized ratio were sug-
gestive of an underlying nephrotic syndrome. However, his 
workup for autoimmunity, infection, and other common 
causes of nephrotic range proteinuria was unrevealing. 
Therefore, we attributed his nephrotic syndrome to his 
known CLL as a diagnosis of exclusion. We discussed a 
potential kidney biopsy with multiple consulting teams to 
further elucidate the mechanism of kidney injury. However, 
this was deferred given that (1) his left kidney was already 
compromised by his left renal vein thrombus and (2) risk of 
acute renal failure if his right-kidney were to be injured dur-
ing said biopsy. Therefore, we decided to initiate chemoim-
munotherapy despite our patient having Rai stage II CLL 
given that there were no other explainable causes of nephrotic 
syndrome. We chose FCR because of its superiority over 
non-fludarabine regimens in young, previously untreated 
patients such as ours, and because his CrCl was well over 80 
mL/min at time of chemotherapy initiation. Although current 
guidelines do not include CLL-associated nephrotic syn-
drome as an indication for treatment, we felt the benefits out-
weighed the risk in this situation especially given his multiple 
complications.
Our case shows that CLL can cause nephrotic syndrome 
in the absence of other etiologies. We also demonstrate that a 
renal biopsy, although helpful, may not always be needed in 
such cases. Our case also shows that CLL-associated 
nephrotic syndrome may be an indication for CLL treatment 
when no other indications exist, in particular with FCR che-
moimmunotherapy in cases without severe renal impairment. 
To our knowledge, this is the only reported case of CLL-
associated nephrotic syndrome that resolved with FCR. It is 
unknown if newer agents (eg, ibrutinib, idelaisib, ventoclax) 
or monoclonal antibodies would have the same effect.
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